These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
436 related articles for article (PubMed ID: 10435593)
1. Role of RhoA activation in the growth and morphology of a murine prostate tumor cell line. Ghosh PM; Ghosh-Choudhury N; Moyer ML; Mott GE; Thomas CA; Foster BA; Greenberg NM; Kreisberg JI Oncogene; 1999 Jul; 18(28):4120-30. PubMed ID: 10435593 [TBL] [Abstract][Full Text] [Related]
2. RhoA-dependent murine prostate cancer cell proliferation and apoptosis: role of protein kinase Czeta. Ghosh PM; Bedolla R; Mikhailova M; Kreisberg JI Cancer Res; 2002 May; 62(9):2630-6. PubMed ID: 11980660 [TBL] [Abstract][Full Text] [Related]
3. Geranylgeranylated proteins are involved in the regulation of myeloma cell growth. van de Donk NW; Lokhorst HM; Nijhuis EH; Kamphuis MM; Bloem AC Clin Cancer Res; 2005 Jan; 11(2 Pt 1):429-39. PubMed ID: 15701825 [TBL] [Abstract][Full Text] [Related]
4. Geranylgeranyl diphosphate-based inhibitors of post-translational geranylgeranylation of cellular proteins. Macchia M; Jannitti N; Gervasi G; Danesi R J Med Chem; 1996 Mar; 39(7):1352-6. PubMed ID: 8691464 [TBL] [Abstract][Full Text] [Related]
5. Lovastatin suppresses invasiveness of anaplastic thyroid cancer cells by inhibiting Rho geranylgeranylation and RhoA/ROCK signaling. Zhong WB; Liang YC; Wang CY; Chang TC; Lee WS Endocr Relat Cancer; 2005 Sep; 12(3):615-29. PubMed ID: 16172195 [TBL] [Abstract][Full Text] [Related]
6. Lovastatin induces apoptosis in malignant mesothelioma cells. Rubins JB; Greatens T; Kratzke RA; Tan AT; Polunovsky VA; Bitterman P Am J Respir Crit Care Med; 1998 May; 157(5 Pt 1):1616-22. PubMed ID: 9603146 [TBL] [Abstract][Full Text] [Related]
7. Lovastatin augments apoptosis induced by chemotherapeutic agents in colon cancer cells. Agarwal B; Bhendwal S; Halmos B; Moss SF; Ramey WG; Holt PR Clin Cancer Res; 1999 Aug; 5(8):2223-9. PubMed ID: 10473109 [TBL] [Abstract][Full Text] [Related]
8. Protein prenylation: key to ras function and cancer intervention? Khosravi-Far R; Cox AD; Kato K; Der CJ Cell Growth Differ; 1992 Jul; 3(7):461-9. PubMed ID: 1419908 [No Abstract] [Full Text] [Related]
9. Activation of the cholesterol pathway and Ras maturation in response to stress. Shack S; Gorospe M; Fawcett TW; Hudgins WR; Holbrook NJ Oncogene; 1999 Oct; 18(44):6021-8. PubMed ID: 10557091 [TBL] [Abstract][Full Text] [Related]
10. Inhibition of epidermal growth factor-induced RhoA translocation and invasion of human pancreatic cancer cells by 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors. Kusama T; Mukai M; Iwasaki T; Tatsuta M; Matsumoto Y; Akedo H; Nakamura H Cancer Res; 2001 Jun; 61(12):4885-91. PubMed ID: 11406567 [TBL] [Abstract][Full Text] [Related]
11. Specific labeling of isoprenylated proteins: application to study inhibitors of the post-translational farnesylation and geranylgeranylation. Danesi R; McLellan CA; Myers CE Biochem Biophys Res Commun; 1995 Jan; 206(2):637-43. PubMed ID: 7826382 [TBL] [Abstract][Full Text] [Related]
12. Inhibition of Ras farnesylation by lovastatin leads to downregulation of proliferation and migration in primary cultured human glioblastoma cells. Bouterfa HL; Sattelmeyer V; Czub S; Vordermark D; Roosen K; Tonn JC Anticancer Res; 2000; 20(4):2761-71. PubMed ID: 10953355 [TBL] [Abstract][Full Text] [Related]
13. Farnesyltransferase inhibitors block the neurofibromatosis type I (NF1) malignant phenotype. Yan N; Ricca C; Fletcher J; Glover T; Seizinger BR; Manne V Cancer Res; 1995 Aug; 55(16):3569-75. PubMed ID: 7627966 [TBL] [Abstract][Full Text] [Related]
14. HMG-CoA reductase inhibitor lovastatin causes reversible cytoskeleton perturbation by RhoA signalling suppression in peritoneal cell line Met5A. Suzuki N; Imai A J Obstet Gynaecol; 2010 May; 30(4):404-7. PubMed ID: 20455727 [TBL] [Abstract][Full Text] [Related]